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Objective: Lomitapide (a microsomal triglyceride transfer protein inhibitor) is an adjunctive treatment
for homozygous familial hypercholesterolaemia (HoFH), a rare genetic condition characterised by
elevated low-density lipoprotein-cholesterol (LDL-C), and premature, severe, accelerated atherosclerosis.
Standard of care for HoFH includes lipid-lowering drugs and lipoprotein apheresis. We conducted a post-
hoc analysis using data from a Phase 3 study to assess whether concomitant apheresis affected the lipid-
lowering efﬁcacy of lomitapide.
Methods: Existing lipid-lowering therapy, including apheresis, was to remain stable from Week 6 to
Week 26. Lomitapide dose was escalated on the basis of individual safety/tolerability from 5 mg to 60 mg
a day (maximum). The primary endpoint was mean percent change in LDL-C from baseline to Week 26
(efﬁcacy phase), after which patients remained on lomitapide through Week 78 for safety assessment
and further evaluation of efﬁcacy. During this latter period, apheresis could be adjusted. We analysed the
impact of apheresis on LDL-C reductions in patients receiving lomitapide.
Results: Of the 29 patients that entered the efﬁcacy phase, 18 (62%) were receiving apheresis at baseline.
Twenty-three patients (13 receiving apheresis) completed the Week 26 evaluation. Of the six patients
who discontinued in the ﬁrst 26 weeks, ﬁve were receiving apheresis. There were no signiﬁcant dif-
ferences in percent change from baseline of LDL-C at Week 26 in patients treated (48%) and not treated
(55%) with apheresis (p ¼ 0.545). Changes in Lp(a) levels were modest and not different between
groups (p ¼ 0.436).
Conclusion: The LDL-C lowering efﬁcacy of lomitapide is unaffected by lipoprotein apheresis.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Medicine and Therapeutics,
3600 Spruce Street, Philadel-
. Cuchel).
Ireland Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
C. Stefanutti et al. / Atherosclerosis 240 (2015) 408e414 4091. Introduction
Homozygous familial hypercholesterolaemia (HoFH) is a rare
genetic disease caused by mutations in genes affecting function-
ality of the low-density lipoprotein receptor (LDLR) [1].
HoFH is characterised by markedly elevated low-density li-
poprotein-cholesterol (LDL-C) levels and premature, severe and
accelerated atherosclerosis [1e3]. The need for aggressive lipid-
lowering therapy for the treatment of FH is recognized by
multiple guidelines worldwide [3e6]. Speciﬁc therapeutic tar-
gets for LDL-C lowering in HoFH are set by the European
Atherosclerosis Society (EAS) at LDL-C <2.5 mmol/L for adults,
or <1.8 mmol/L in adults with atherosclerotic cardiovascular
disease [1]. In spite of treatment with traditional lipid-lowering
therapies, including statins and ezetimibe, LDL-C in patients
with HoFH typically remains above goal levels [7,8]. Therefore,
the standard of care for HoFH includes lipoprotein apheresis
(LA), where available, which transiently removes LDL-C from
plasma during extracorporeal circulation with the aim of
delaying the onset and progression of cardiovascular disease
[3,9e12].
Although LA (a technique that selectively removes apolipo-
protein B (apoB)-containing lipoproteins and spares negatively-
charged molecules such as high-density lipoprotein-cholesterol
[HDL-C] [13e16]) has largely supplanted non-selective thera-
peutic plasma exchange (TPE) [12,15,16], both are still used to treat
HoFH. As a result of low catabolic rate and ongoing production of
LDL, both LA and TPE methods lower LDL-C levels only transiently
[17], and the procedure is generally repeated every 7e14 days,
consistent with international clinical recommendations [3,18,19].
Although effective at lowering LDL-C, apheresis is not univer-
sally available due to a range of factors that include the need for
specialisation and training, and costs associated with providing the
treatment. Additionally, not all patients are suited to apheresis due
to the frequency of treatments (at least bi-weekly), and the need to
maintain vascular access. There is, therefore, a need for additional
therapies in patients with HoFH.
Lomitapide is a small-molecule microsomal triglyceride transfer
protein (MTP) inhibitor and is approved in several countries
worldwide as an adjunct to other lipid-lowering therapies, with or
without apheresis, in adult patients with HoFH [20]. The safety and
efﬁcacy of lomitapide was evaluated in a Phase 3 study
(NCT00730236), which included patients receiving apheresis.
Lomitapide and apheresis work via different modes of action,
therefore it is reasonable to suggest that their effects may be in-
dependent. A post-hoc analysis using data from this study was
conducted to ascertain if concomitant apheresis affected the lipid-
lowering efﬁcacy of lomitapide.
2. Methods
2.1. Study design and treatment
The study design, patient population and results have been
described previously [21] and summarized in the supplemental
material.
Apheresis was provided either via LA or TPE. Techniques and
schedules employed by the study investigators reﬂected local
clinical practice, individual patient requirements and physician
choices [21]. Mean volume of blood or plasma processed and
plasma substituted (for patients treated with TPE) were calcu-
lated according to apheresis technique and local clinical prac-
tice. Gender, haematocrit, body mass index and pre-treatment
LDL-C were used to determine the appropriate plasma or blood
volume to be processed. During extracorporeal procedures,heparin was preferred over acid-citrate dextrose as an
anticoagulant.
Fasting lipid proﬁles were obtained with recognition that
apheresis treatment causes a sharp drop in LDL-C, followed by a
rebound phase. Therefore, in patients undergoing apheresis, and
according to the protocol, it was important that lipid parameters
were evaluated at a time that was as close as possible to, and before
the scheduled apheresis treatment. Once established, this time
point was to be maintained relative to the previous apheresis ses-
sion, so that pre-apheresis lipid assessments were always per-
formed at the same point on the LDL rebound curve. Per protocol,
post-apheresis samples were not routinely obtained; therefore,
time-averaged (mean interval) values for lipid parameters [17]
were not calculable.
During the 6-week run-in phase, a stable-frequency apheresis
regimen (e.g., apheresis every 7e14 days, with some ﬂexibility for
individualisation) was established andwas to bemaintained during
the 26-week efﬁcacy phase. If the visit schedule was inconsistent
with a patient's apheresis schedule, then the investigator was to
request a protocol deviation. If a patient was unable to come for an
apheresis treatment per his/her usual regimen, apheresis was to be
rescheduled as soon as possible. If apheresis was missed at the time
of a study visit, then blood samples were taken before apheresis
treatment and as close as possible to the apheresis regimen
established during the run-in phase, or as altered during the safety
phase. At Week 2 and Week 0 (baseline), Week 18, and Week 26
(primary efﬁcacy time point), fasting lipids were drawn just prior to
the apheresis treatment and apheresis must have occurred ±1 day
from the regimen established during the run-in phase. Following
the efﬁcacy phase, patients entered a 52-week safety phase during
which statins and other lipid-lowering therapies (including fre-
quency of apheresis) could be adjusted on a case-by-case basis at
the physician and patient's discretion based on established protocol
criteria.2.2. Statistical analysis
The post-hoc analysis presented here was conducted using data
collected during the period of the Phase 3 study (baseline to Week
26) that assessed efﬁcacy with no changes to background therapy
allowed. An analysis using a mixed-model repeated-measures
analysis, accounting for multiple observations per subject, was
conducted to assess potential differences in percent change from
baseline to Week 26 in lipid parameters for subjects who did and
who did not receive apheresis. The model included treatment with
apheresis (yes, no), baseline lipid level, and categorical study week
as ﬁxed parameters and a study week-by-apheresis interaction. A t-
test was applied to assess the differences in least square means for
percent change from baseline to Week 26 between the two sub-
groups. Fisher's Exact test was used to evaluate the signiﬁcance of
differences between attainment of LDL-C thresholds observed in
patients receiving apheresis versus those not. Wilcoxon rank sum
exact test was used to assess change in hepatic fat at Week 26 from
baseline comparing subjects on apheresis versus no apheresis.
Spearman rank correlation was used to assess the relationship
between percent change in hepatic fat and the change from base-
line in LDL-C at Week 26 independent of apheresis. The intent-to-
treat population was used for the analysis, and missing values
were not imputed.
A post-hoc estimation of statistical power based on the number
of subjects receiving/not receiving apheresis (n ¼ 18 versus 11)
revealed that this sample size would have 80% power to detect a
32% difference in percent change in LDL-C from baseline between
apheresis groups.
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3.1. Patients
Overall patient characteristics and results have been presented
previously [21].
Of the 29 patients who entered the efﬁcacy phase, 18 (62%) were
receiving either LA or TPE at baseline (Table 1). Baseline charac-
teristics were well matched between patients who received
apheresis and those who did not. Twenty-three patients (13
receiving apheresis) completed the Week 26 evaluation (Fig. 1).
Six patients discontinued during the efﬁcacy phase (ﬁve due to
adverse events [AEs] [four gastrointestinal [GI] AEs], one headache,
and one patient withdrew consent). Five of the six patients that
discontinued were receiving apheresis (four withdrew due to AEs:
one due to headache, and three due to GI AEs) (Fig. 1).
The apheresis technique used was region dependent. All South
African and Canadian patients and one US patient received TPE
(n ¼ 7). All Italian and the remaining US patients received LA
(n ¼ 11).
Thirteen patients received apheresis once every two weeks. A
further four patients receivedweekly apheresis. In the US, Canadian
and South African centres the predominant schedule was once
every two weeks. In the Italian centres, two patients received
apheresis every week, one patient was treated once every two
weeks, and one patient once every 6 weeks.3.2. Lomitapide efﬁcacy in patients receiving and not receiving
apheresis during the efﬁcacy phase
The efﬁcacy of lomitapide in the overall population has been
reported [21]. By the end of the efﬁcacy phase (Week 26), during
which apheresis schedules were to remain consistent, lomitapide
was associated with a similar mean percent reduction in LDL-C
from baseline irrespective of whether patients received apheresis
or not (ITT population; Table 2). According to a mixed model
repeated measures, overall percent reductions in LDL-C from
baseline were 51.0% in all patients, e48.0% in those on apheresis
and55.1% in those not on apheresis (p¼ 0.545). Similarly, percent
reductions in non-HDL-C (48.3% versus 54.2%; p ¼ 0.613), total
cholesterol (43.8% versus 49.8%; p ¼ 0.575) and apoB (47.9%
versus 53.2%; p ¼ 0.625) were not signiﬁcantly different between
those on apheresis and those not (Table 2). Lipoprotein(a) [Lp(a)]
levels did not change markedly over the course of the study, and
percent reductions were not signiﬁcantly different between the
two groups (12.8% versus 23.1%; p ¼ 0.436), although baseline
levels were lower in the apheresis group than in the non-apheresis
group (2.3 mmol/L versus 3.5 mmol/L) (Table 2). Triglycerides and
Lp(a) were also assessed using non-parametric methods and mixed
model methods on the log results given the distribution of these
parameters. These analyses chieﬂy conﬁrmed there was noTable 1
Baseline characteristics of patients.
Parameter Overall
(n ¼ 29)
Apheresis
(n ¼ 18)
No apheresis
(n ¼ 11)
p-valuea
Age (years), mean ± SD 31 ± 11 31 ± 10 30 ± 12 0.890
Male, n (%) 16 (55%) 11 (61%) 5 (46%) 0.429
BMI (kg/m2), mean ± SD 25.8 ± 5.4 25.0 ± 3.0 27.3 ± 8.0 0.280
Statin therapy, n (%) 27 (93%) 16 (88.9%) 11 (100%) 0.286
Ezetimibe plus statin, n (%) 22 (69%) 14 (67%) 8 (73%) 0.070
LDL-C (mmol/L), mean ± SD 8.7 ± 3.0 8.4 ± 2.8 9.2 ± 3.2 0.509
LDL-C (mg/dL), mean ± SD 336 ± 114 325 ± 108 355 ± 125 0.509
a Apheresis versus no apheresis.signiﬁcant difference between those on apheresis and those not.
The sample size of the study was not sufﬁcient to enable sta-
tistical signiﬁcance to be declared on the difference in percent
reduction in LDL-C from baseline between apheresis groups.
3.3. Attainment of LDL-C threshold and apheresis reductions
Despite intensive lipid-lowering management, mean LDL-C
levels at baseline were 8.4 mmol/L for patients receiving apher-
esis and 9.2 mmol/L for those not receiving apheresis (Table 1) prior
to lomitapide treatment. No subject had reached targets recom-
mended in guidelines set by the recent European Atherosclerosis
Society consensus statement [1]. We analysed attainment of LDL-C
below recommended thresholds over the course of the study and
ascertained if differences between subjects receiving apheresis or
not existed. When considering all subjects enrolled (n ¼ 29), about
a quarter of subjects reached LDL-C levels <2.5 mmol/L at Week 26,
with no signiﬁcant differences in attainment of LDL-C thresholds
observed between those receiving apheresis and those not (Table 3,
p ¼ 0.4327 and p ¼ 1.000 for thresholds of 2.5 mmol/L and
1.8 mmol/L, respectively). When analysis was conducted on data
collected during the entire 78 week-long trial, about half (55%) the
subjects attained an LDL-C level of <2.5 mmol/L and about a third
(34%) subjects attained an LDL-C level <1.8 mmol/L at least once.
Two of the patients who discontinued the study (one receiving, one
not receiving apheresis) achieved an LDL-C level <2.5 mmol/L prior
to discontinuation.
During the safety phase, when concomitant lipid-lowering
therapies could be modiﬁed at the discretion of the individual
prescriber and patient, the apheresis regimen of six of the 13 pa-
tients (46%) receiving apheresis at the end of the efﬁcacy phase
underwent a change that wasmaintained until the end of the study.
Three patients stopped apheresis (Fig. 2AeC) and a further three
patients decreased the frequency of apheresis treatments
(Fig. 2DeF) [21]. In general, LDL-C levels weremaintained following
either a reduction in the frequency or discontinuation of apheresis
(Fig. 2AeF). Similar results were observed with apoB levels (data
not shown).
3.4. Safety
Adverse event (AE) reporting in the study was for lomitapide
associations only. Therefore, only limited comment can be made on
the side-effect proﬁle of apheresis in this setting. No side effects
resulting in failure to return for an apheresis sessionwere recorded.
For lomitapide, the full safety and tolerability data from the
Phase 3 study have been reported previously [21]. Brieﬂy, four
patients (three receiving apheresis) had conﬁrmed elevations in
aminotransferases between 5 and 10 upper limit upper limit of
normal that resolved with dose reduction or interruption of study
drug. The most commonly reported AEs were gastrointestinal (GI)-
related, predominantly assessed as mild-to-moderate in intensity.
There was no difference between the incidence of GI- and non-GI-
related disorders for patients receiving apheresis and those not
receiving apheresis; however, ﬁve of the six discontinuations in the
study were for patients receiving apheresis.
Withdrawals were due to AEs in four of the ﬁve patients
receiving apheresis who discontinued the study (Fig. 2). These four
patients were receiving a range of daily doses of lomitapide (5, 10
and 40 mg). The number of withdrawals was too low for mean-
ingful comparisons to be made.
Mean hepatic fat in 21 patients with evaluable nuclear magnetic
resonance spectroscopy scans from both treatment groups com-
bined was 1.0% (range, 0e3.8) at baseline, and 8.3% (0.8e33.6) at
Week 26. Percent change in hepatic fat was negatively associated
Fig. 1. Patient disposition.
Table 2
Percent change from baseline in lipid and lipoprotein levels at Week 26 in patients with and without apheresis treatment using Mixed Model Repeated Measures.a
Parameter Overall (n ¼ 29) Apheresis (n ¼ 18) No apheresis (n ¼ 11) p-valueb
Baseline (range) % Change Baseline (range) % Change Baseline (range) % Change
TC, mmol/L 11.1 (4.9e18.7) 46.3 10.7 (4.9e16.4) 43.8 11.8 (6.3e18.7) 49.8 0.575
LDL-C, mmol/L 8.7 (3.9e14.6) 51.0 8.4 (3.9e12.9) 48.0 9.2 (4.3e14.6) 55.1 0.545
Non-HDL, mmol/L 10.0 (4.1e17.1) 50.7 9.6 (4.1e15.4) 48.3 10.7 (5.0e17.1) 54.2 0.613
TG, mmol/L 2.7 (0.8e6.5) 43.3 2.8 (0.8e6.5) 45.2 2.5 (1.3e4.6) 41.2 0.777
ApoB, g/L 2.6 (1.2e4.3) 50.1 2.5 (1.2e3.6) 47.9 2.8 (1.4e4.3) 53.2 0.625
HDL-C, mmol/L 1.1 (0.7e1.8) 11.3 1.1 (0.9e1.7) 10.3 1.1 (0.7e1.8) 12.4 0.760
ApoA-I, g/L 1.1 (0.6e1.9) 10.6 1.2 (0.8e1.6) 11.3 1.1 (0.6e1.9) 9.2 0.730
Lp(a), mmol/L 2.8 (0.6e12.1) 17.2 2.3 (0.7e4.7) 12.8 3.5 (0.6e12.1) 23.1 0.436
a Mixed model includes treatment with apheresis (yes/no), baseline lipid level, and categorical study week as ﬁxed parameters and a study week-by-apheresis interaction.
b Apheresis versus no apheresis.
Table 3
LDL-C treatment goal attainment in the overall population and in subjects with and without apheresis treatment over the course of the trial (efﬁcacy plus safety phases).
LDL-C, mmol/L (mg/dL) Overall (n ¼ 29) Apheresis (n ¼ 18) No apheresis (n ¼ 11)
<2.5 (<100) <1.8 (<70) <2.5 (<100) <1.8 (<70) <2.5 (<100) <1.8 (<70)
At Week 26, n (%) 8 (28%) 1 (3%) 4 (22%) 1 (6%) 4 (36%) 0
At any time, n (%) 16 (55%) 9 (31%) 8 (44%) 5 (28%) 8 (73%) 4 (36%)
C. Stefanutti et al. / Atherosclerosis 240 (2015) 408e414 411with change in LDL-C at Week 26 independent of apheresis
(p ¼ 0.754 for apheresis versus non-apheresis; Spearman rank
correlation for change from baseline between LDL-C and hepatic
fat ¼ e0.4207, p ¼ 0.05). Similar to the recorded GI AEs, there was
no difference in the hepatic fat content at Week 26 between pa-
tients receiving apheresis and those not receiving apheresis. Mean
hepatic fat data at Week 26 are presented in Table 4.
4. Discussion
Treatment with lomitapide signiﬁcantly lowered LDL-C in pa-
tients with HoFH receiving maximal standard lipid-lowering ther-
apy [21]. The current post-hoc analysis showed that the LDL-C-
reducing efﬁcacy of lomitapide is independent of whether or not
patients received apheresis in this study. The percent reduction in
LDL-C level in either group (apheresis or no apheresis) and the
number of patients who reached EAS treatment goals of LDL-C
<1.8 mmol/L and <2.5 mmol/L [1] during the trial were similar
among patients who received apheresis versus those who did not,
and were consistent with those observed in the overall population
[21]. Individual proﬁles of the patients who discontinued apheresis
after Week 26 do not appear to indicate any clinically meaningful
changes in LDL-C levels after stopping the procedure [21].
These ﬁndings support the hypothesis that the efﬁcacy oflomitapide is unaltered by the application of apheresis and that the
combination of the two therapeutic approaches provides additional
lipid-lowering beneﬁt to patients on apheresis. Some patients were
able to adjust their apheresis schedules while receiving lomitapide.
This could form the basis of an expanded multimodal approach to
lipid lowering whereby the relative doses of lomitapide, statins and
apheresis could be modulated to suit individual patient responses,
tolerances and lifestyle requirements. A multimodal approach of
this type may be particularly relevant in HoFH, in which different
mutation proﬁles confer different levels of key receptor and peptide
function in lipoprotein catabolism.
To date, lomitapide is the only drug among the new generation
of lipid-lowering agents to have been tested in clinical settings that
include apheresis, and to be approved for combination therapy in
patients with HoFH. Mipomersen is also approved in the United
States as an adjunctive lipid-lowering therapy for HoFH. However,
the Phase 3 trial for mipomersen did not include patients receiving
apheresis, and the product label speciﬁcally states that mipo-
mersen use is not recommended in patients undergoing LA [22,23].
PCSK9 inhibitors are currently in Phase 3 development as lipid
lowering therapies, and have been tested in patients with HoFH.
Results for the PCSK9 inhibitor evolocumab indicate that this
approach is effective in at least some patients with HoFH,
depending upon their level of receptor activity [24]. Interestingly,
Fig. 2. Individual LDL-C proﬁles for patients who discontinued apheresis (AeC) or extended apheresis intervals (DeF) during the safety phase of the trial. Lipid parameters were
evaluated at a time that was as close as possible to, and before, the scheduled apheresis treatment. Once established, this time point for lipid assessment blood draws was
maintained, relative to the previous apheresis visit, so that lipid assessments were always performed at the same point on the LDL rebound curve.
Table 4
Hepatic fat levels at baseline and Week 26 in the overall population of lomitapide-treated patients and those treated with and without apheresis (efﬁcacy plus safety phases).
Parameter (%) Overall (N ¼ 21) Apheresis (n ¼ 12) No apheresis (n ¼ 9)
Value % Change Value % Change Value % Change
Baseline
Mean (SD) 1.0 (1.0) e 1.4 (1.1) e 0.6 (0.5) e
Median (25%, 75% IQR) 0.7 (0.4, 1.1) e 1.0 (0.4, 2.2) e 0.7 (0.2, 0.7) e
MineMax 0.0e3.8 e 0.4e3.8 e 0.0e1.7 e
Week 26
Mean (SD) 8.3 (7.5) 7.3 (6.8) 9.1 (9.2) 7.7 (8.3) 7.3 (4.7) 6.8 (4.4)
Median (25%, 75% IQR) 6.6 (3.8, 11.9) 5.7 (2.7, 11.0) 6.9 (3.4, 12.2) 5.7 (2.0, 11.2) 6.0 (4.8, 9.5) 5.7 (4.3, 9.3)
MineMax 0.8e33.6 0.4e29.9 0.8e33.6 0.4e29.9 1.6e16.3 0.9e14.5
p-valuea e e e e e 0.754
IQR, interquartile range.
a Descriptive p-value based on Wilcoxon rank sum exact test for change in hepatic fat at Week 26 from baseline comparing subjects on apheresis versus no apheresis.
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increase the apparent efﬁcacy of PCSK9 inhibitors in combination
with apheresis. The ongoing phase 2/3 TAUSSIG study of evolocu-
mab in severe familial hypercholesterolaemia (FH) (n¼ 5) included
two patients receiving apheresis, but analysis by apheresis is not
available and the sample size is extremely small [26]. Thus, the
efﬁcacy of these drugs in presence of apheresis remains to be
determined.
MTP inhibitors are known to affect hepatic secretion of apoB-
containing lipoproteins and lomitapide has been shown to
decrease the production of LDL-apoB in patients with HoFH [27]. It
is therefore probable that lomitapide favourably affects the
rebound curve of LDL and other apoB-containing lipoproteins
characteristic of apheresis by limiting the secretion of these lipo-
proteins. Data from a recently published case report supports this
possibility [28]. Based on how the drug is metabolised and its low
systemic availability [29], it is unlikely that apheresis affects
lomitapide levels; however, this question was not directly assessed
in the Phase 3 study. Of the six patients in the studywho stopped or
altered their apheresis schedule, no apparent rebound of LDL-C orapoB levels was observed over the 78-week study period. Addi-
tional data in more patients would be needed to conﬁrm these
ﬁndings.
In this post-hoc analysis, Lp(a) levels did not change signiﬁ-
cantly for either of the apheresis groups. This is not a surprising
ﬁnding given that patient numbers are small, and the Lp(a) levels
are higher in the non-apheresis group. This latter ﬁnding is ex-
pected because apheresis removes apoB-containing lipoproteins
from blood. This post-hoc analysis was not powered for signiﬁ-
cance. However, it is intriguing to observe that Lp(a) levels at
baseline are approximately 50% higher in the non-apheresis group
than those in the apheresis group, and mean reductions in Lp(a)
over the course of the study were twice that in the non-apheresis
group compared to the apheresis group. A larger sample size may
provide data on which ﬁrm conclusions can be made about the
relative abilities of lomitapide and lomitapide/apheresis combina-
tion therapy to control the rebound dynamics of Lp(a).
As compared to the modest effect of lomitapide in lowering
Lp(a), both apheresis and mipomersen reduce circulating levels of
Lp(a) more substantially [30,31]. This activity may confer an
C. Stefanutti et al. / Atherosclerosis 240 (2015) 408e414 413additional cardioprotective effect, as elevated Lp(a) is an indepen-
dent risk factor for CVD in FH [32]. The effect of Lp(a) reduction on
long-term patient outcomes in FH remains to be determined;
nevertheless, the differential effects of lomitapide, mipomersen,
apheresis or novel targeted therapeutic approaches on Lp(a) levels
[32] underscore the need to considermultimodal therapies in HoFH
according to individual patient needs.
Safety data for lomitapide, including hepatic fat and GI tolera-
bility, did not appear to differ between patients on apheresis
compared with those who were not. The low number of patients in
the analysis makes it difﬁcult to make conclusions about the relative
GI tolerability of lomitapide in combination with apheresis versus
lomitapide alone. Of the six patients who discontinued the study,
ﬁve were receiving apheresis, including three who discontinued
because of GI AEs. This highlights the need to individualise therapy in
HoFH patients, and for physicians and patients to be prepared to
adjust the relative doses of apheresis and lomitapide to enable pa-
tients to remain on maximally effective combination regimens.
We recognize that this analysis has some limitations. Firstly, in
the study protocol, the apheresis schedule was not ﬁxed. As such,
apheresis treatment was individualised on a per-patient basis, also
taking into account physician experience. Therefore, not all patients
received an optimal apheresis treatment schedule (in particular,
one patient received apheresis once every 6 weeks). Secondly, the
analysis by apheresis treatment was post hoc, and not pre-speciﬁed
in the original protocol. As such, the study was not powered to
detect small differences in response to treatment between apher-
esis treatment groups. Additionally, the small number of trial par-
ticipants did not allow us to explore possible differences in
response according to apheresis technique, which was not stan-
dardized and was undertaken according to site-speciﬁc protocols.
Further, and in contrast to the TESLA trial of evolocumab in HoFH
[24], a sub-analysis by receptor functionality was not possible
based on study design that allowed for a maximum tolerated dose
to be individually determined. However, due to the mode of action
of lomitapide as an inhibitor of MTP, we would not expect LDL-
receptor functionality to signiﬁcantly affect efﬁcacy, in contrast to
the situation with statins and other agents that rely on functioning
LDL-receptor. Finally, because analysis by apheresis was not deﬁned
a priori, AE data were collected and formally analysed only in
relation to lomitapide, not apheresis.
Further data are required on the association between the effects
of lomitapide and in particular LA (rather than TPE). Speciﬁc data
from more controlled settings with only selectively chosen apher-
esis techniques would be most valuable. Importantly, given the
signiﬁcant add-on effect of lomitapide, it would be interesting to
investigate whether it is possible to modulate the volume of blood/
plasma processed and to adjust the frequency of apheresis with the
aim of making substantial, positive qualitative changes for patients
who are candidates for lifelong therapy while not losing any po-
tential beneﬁcial effects of decreased LDL-C. Although the possi-
bility to conduct larger clinical trials is hindered by the relative
rarity of HoFH, it would be valuable to examine the relative clinical
performance of lomitapide with and without standardized apher-
esis protocols, and to determine overall healthcare costs associated
with the delivery of lomitapide and apheresis monotherapies,
where data are currently lacking.
In conclusion, lomitapide, added to a low-fat diet and ongoing
standard lipid-lowering treatment including apheresis, signiﬁ-
cantly reduced LDL-C in adult patients with HoFH to a similar de-
gree whether the patient was receiving concomitant apheresis or
not. Notably, different centres used different apheresis techniques
and schedules in a manner analogous to a real-world, non-clinical
trial situation. More studies are needed aimed at making substan-
tial, positive qualitative changes for patients who are candidates forlifelong therapy while not losing any potential beneﬁcial effects of
decreased LDL-C. Information of this type could be used to inform
the design future of individualised, multimodal pharmacotherapy/
apheresis regimens.
Translational perspective
Due to the difﬁculties inherent in treating homozygous familial
hypercholesterolaenia (HoFH), lipoprotein apheresis (LA) is part of
the standard of care. Lomitapide, an oral agent for HoFH, was found
to exert a lipid-lowering effect independently of LA. Therefore, both
therapies can be applied concurrently without loss of efﬁcacy.
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